New nanoparticles for treating advanced triple negative breast cancer
Official title: Drug combination nanoparticles for advanced treatment of metastatic TNBC
Funded at University of Washington · NIH-10807038 · Data updated 2026-11-12
This study is testing a new way to deliver two chemotherapy drugs together using tiny particles, aiming to make treatment more effective and less harmful for people with metastatic triple negative breast cancer, especially those who have few options left.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Washington NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project start | March 10, 2023 |
| Project end | February 28, 2026 |
| Funding year | 2024 |
| Award (this year) | $168,413 |
| NIH project number | 5R21CA273739-02 |
| Project ID | NIH-10807038 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with metastatic triple negative breast cancer who have limited treatment options.
✕Less likely to help
Patients with non-metastatic breast cancer or those with other subtypes of breast cancer may not benefit from this research.
What this research studies
This research focuses on developing innovative nanoparticles that can deliver a combination of two chemotherapy drugs, gemcitabine and paclitaxel, specifically targeting metastatic triple negative breast cancer (TNBC). The approach aims to enhance the effectiveness of these drugs while minimizing systemic toxicity, which is a common issue with traditional chemotherapy. By using a dual-drug loaded nanoparticle system, the researchers hope to improve the synchronization and prolonged delivery of the medications, potentially leading to better treatment outcomes for patients. The study is particularly relevant for those who have limited options due to the aggressive nature of TNBC.
Why it matters
Potential benefit: If successful, this research could significantly improve survival rates and quality of life for patients with metastatic triple negative breast cancer.
How similar studies have gone: Other research has shown promise in using nanoparticle delivery systems for cancer treatment, indicating that this approach could be effective.
Where this research is happening
-
University of Washington
Seattle, United States Active
Researchers
- Principal investigator: Mu, Qingxin — University of Washington
- Study coordinator: Mu, Qingxin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.